Cerebral Ischemia is Associated With Corneal Nerve Loss and Brain Atrophy in Mild Cognitive Impairment and Dementia

Georgios Ponirakis  
Weill Cornell Medicine - Qatar

Ahmed Elsotouhy  
Hamad Medical Corporation

Hanadi Al Hamad  
Hamad Medical Corporation

Surjith Vattoth  
University of Arkansas for Medical Sciences

Ioannis N. Petropoulos  
Weill Cornell Medicine - Qatar

Adnan Khan  
Weill Cornell Medicine - Qatar

Hoda Gad  
Weill Cornell Medicine - Qatar

Fatima Al-Khayat  
Weill Cornell Medicine - Qatar

Mani Chandran  
Hamad Medical Corporation

Marwan Ramadan  
Hamad Medical Corporation

Marwa Elorrabi  
Hamad Medical Corporation

Masharig Gadelseed  
Hamad Medical Corporation

Rhia Tosino  
Hamad Medical Corporation

Priya V. Gawhale  
Hamad Medical Corporation

Maryam Alobaidi  
Hamad Medical Corporation

Shafi Khan
Research

Keywords: Ischemic lesions, surrogate marker, corneal confocal microscopy, corneal nerve fibers, brain atrophy, dementia, mild cognitive impairment

DOI: https://doi.org/10.21203/rs.3.rs-101841/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Background

The prevalence of cerebral ischemia increases with age and is a risk factor for cognitive impairment and dementia. This study assessed the association of brain ischemic lesions with the severity of neurodegeneration utilizing brain volumetric MRI and corneal confocal microscopy (CCM) in patients with mild cognitive impairment (MCI) and dementia.

Methods

Subjects with MCI and dementia without diabetes underwent cognitive screening, CCM, assessment of ischemic lesions and quantitative brain MRI.

Results

Of 63 subjects with MCI (n=44) and dementia (n=19), 11 had no ischemia, 32 had subcortical ischemia and 20 had both cortical and subcortical ischemia. Subjects with MCI and dementia had comparable percentage of cerebral ischemia (P=0.25). Global cognitive function was significantly impaired in subjects with both cortical and subcortical ischemia (P<0.05) but not in those with subcortical ischemia (P=0.10) compared to those without ischemia. Corneal nerve fiber density (CNFD) (P<0.01), branch density (CNBD) (P<0.05) and fiber length (CNFL) (P<0.01) were significantly lower in subjects with both cortical and subcortical ischemia compared to those without ischemia and CNFD (P<0.05), CNBD (P<0.05) and CNFL (P<0.05) were significantly lower in subjects with both cortical and subcortical ischemia compared to those with subcortical ischemia. In subjects with both cortical and subcortical ischemia whole brain (P<0.01) and hippocampal volume (P<0.001) were significantly lower and ventricle volume was higher (P<0.05) compared to those without ischemia and hippocampal volume (P<0.01) was lower and ventricle volume was higher (P<0.01) in subjects with both cortical and subcortical ischemia compared to those with subcortical ischemia.

Conclusions

The presence of cortical and subcortical ischemia is associated with cognitive impairment, corneal nerve loss and brain atrophy in patients with MCI and dementia.

Background

Cerebrovascular ischemic lesions in the brain are present in 11-94% of people aged ≥60 years [1] and increase the risk of cognitive impairment [2] and dementia [3, 4], depending on the person's age, education and lifestyle, as well as the location and size of ischemic load [5]. Ischemic lesions are incomplete infarctions due to reduced blood flow caused by critical stenosis in small vessels in the white matter of the brain [5] and can increase and decrease in size [6]. Management of hypertension [7, 8] and diabetes [9, 10], antiplatelet therapy [11] or use of calcium-channel blockers [12] may prevent or reduce ischemic
lesions. There is limited evidence on the relationship between the presence and severity of ischemic lesions and neurodegeneration [13, 14].

Patients with ischemic lesions and lacunar stroke have impaired executive function and reduced brain volume [13]. Corneal confocal microscopy (CCM) has shown significant corneal nerve loss in patients with TIA [15] and acute ischemic stroke [16]. Furthermore, corneal nerve loss has been associated with the presence of ischemic lesions in patients with acute ischemic stroke after adjusting for age, diabetes, gender, dyslipidemia and smoking [14]. We have also previously reported that patients with mild cognitive impairment (MCI) and dementia have significant corneal nerve loss which is associated with the severity of cognitive impairment and disability [17, 18].

The aim of this study was to assess the association between the presence and severity of cerebral ischemic lesions with neurodegeneration quantified by brain volumetric MRI and CCM in patients with MCI and dementia, including Alzheimer's disease (AD), vascular dementia (VaD) and mixed dementia. The severity of neurodegeneration was compared between patients without and with ischemic lesions in the subcortex and both subcortex and cortex. This study excluded those with diabetes as this is a confounding factor for corneal nerve loss [19].

Methods

Patients with MCI, dementia, including AD, VaD and mixed AD aged 60-85 years old were recruited from the Geriatric and Memory clinic in Rumailah Hospital, Doha, Qatar between 18/09/16 and 31/07/19. Patients with severe anxiety, severe depression, Parkinson's disease, frontotemporal dementia and Lewy body dementia, hypomania, and severe dementia who were unable to cooperate were excluded. Additionally, patients with peripheral neuropathy including diabetes, vitamin B$_{12}$ deficiency, hypothyroidism, HIV infection and hepatitis C were excluded. Patients with dry eyes, corneal dystrophies, ocular trauma or surgery in the preceding 12 months were excluded. This study was approved by the Institutional Review Board of Weill Cornell Medicine in Qatar and Hamad Medical Corporation and all participants gave informed consent to take part in the study. The research adhered to the tenets of the declaration of Helsinki.

Demographic and metabolic measures

Age, gender, ethnicity, blood pressure, weight, body mass index (BMI), HbA1c, cholesterol, triglycerides, thyroid stimulating hormone (TSH), free thyroxine (FT4) and vitamin B$_{12}$ were recorded.

Cognitive screening

Cognitive screening was performed using the Montreal Cognitive Assessment (MoCA) test. The MoCA assesses seven cognitive domains including visuospatial/executive, naming, memory, attention, language, abstraction and delayed recall giving a total score of 30. A score of ≤26 indicates cognitive
impairment. A point was added for individuals who had formal education \( \leq \) 6th grade. Cognitive symptom duration was estimated from the clinical history obtained from relatives and participants.

**Diagnosis**

The diagnosis of MCI and dementia, including AD, VaD and mixed AD were based on the ICD-10 criteria [20]. The diagnosis was made according to consensus decision by geriatricians, geriatric psychiatrists and neurologists to exclude reversible, complex and young-onset dementia. The diagnoses of MCI and dementia were based on a patient history and examination, which include (1) presenting complaint and history of illness; (2) comprehensive history of each of the cognitive domains using MoCA; (3) psychiatric history for ruling out depression, mood disorders, and psychosis; (4) medical history including episodes of delirium and other medical comorbidities; (5) medication history; (6) functional history of basic daily living activities. A comprehensive organic work-up including blood tests and brain imaging was undertaken to exclude other potentially reversible causes of cognitive decline such as tumors, subdural hematoma or normal pressure hydrocephalus. The diagnosis of AD was based on typical features of AD on MRI, including volume loss of hippocampi, entorhinal cortex, and amygdala. The diagnosis of mixed AD was based on the presence of AD and significant vascular changes. The diagnosis of probable or possible VaD was based on multiple large vessel infarcts or a single strategically placed infarct in the angular gyrus, thalamus, basal forebrain, or posterior (PCA) or anterior cerebral artery (ACA) territories, and multiple lacunes in basal ganglia and white matter, extensive periventricular white matter lesions or combinations thereof.

**Brain MRI acquisition**

MRI was performed on a superconductive magnet operated at 3T (Skyra, Siemens) at the MRI unit in Rumailah Hospital. The subject's head was immobilized with a head holder to minimize motion artifacts. A T1-weighted 3D magnetisation prepared rapid acquisition gradient echo sequence (MPRAGE) was obtained in the sagittal plane with a 1 mm slice thickness, repetition time of 1900 ms, echo time of 2.67 ms and 2.46 ms, inversion time of 1100 ms and 900 ms, flip angle of 9 degree and 15 degree, and FOV=240 x 100. Coronal and axial reformatted MPRAGE images are reconstructed from the sagittal 3D sequence.

**Ischemic lesion assessment**

The presence of ischemic lesions was defined as hyperintense foci on T2 and FLAIR. Small vessel disease (SVD) was assessed by the presence of white matter hyperintensities (WMH) in cortical, subcortical or both regions. Infarcts including lacunes, large infarcts and hemorrhage were not included in the analysis. Foci that were hyperintense on T2 and showed central low signal with a peripheral rim of hyperintensity on FLAIR were defined as lacunes. Larger areas of gliosis/encephalomalacia following a vascular pattern or diffusion restricting acute ischemic lesions were defined as infarcts. Subcortical ischemia was based on the presence of ischemic lesions located in the subcortical white matter, deep
grey nuclei including basal ganglia, thalami, and mesial temporal lobe. Cortical ischemia was based on the presence of ischemic lesions located in the cerebral convexity cortex.

**Brain volume analysis**

MRI T1-weighted 3D MPRAGE sequences were processed using NeuroQuant (NQ), an FDA approved fully automated software [21, 22] to measure brain volumes. The brain volume was adjusted for percentage of intracranial volume (ICV) which includes all segmented structures to minimize the impact of the head size as a confounding factor. The ICV percentage of the whole brain, cortical gray matter, ventricle, hippocampi, frontal, temporal and parietal lobe are included in this study.

**Corneal confocal microscopy**

CCM analysis was performed with the Heidelberg Retinal Tomograph III Rostock Cornea Module (Heidelberg Engineering GmbH, Heidelberg, Germany). The cornea was locally anesthetized by instilling 1 drop of 0.4% benoxinate hydrochloride (Chauvin Pharmaceuticals, Chefaro, UK) and Viscotears gel (Carbomer 980, 0.2%, Novartis, UK) was used as the coupling agent between the cornea and the TomoCap as well as between the TomoCap and the objective lens. Subjects were instructed to fixate on a target with the eye not being examined. Several scans of the sub-basal nerve plexus in the central cornea were captured per eye for ~2 min. The field of view of each image is 400X400 µm. At a separate time, three high clarity images per eye were selected by one researcher blind to the patient diagnosis using established criteria based on depth, focus position and contrast [23]. Corneal nerve fiber density (CNFD) (fibers/mm²), branch density (CNBD) (branches/mm²) and fiber length (CNFL) (total fiber length mm/mm²) were quantified manually using CCMetrics, a validated image analysis software [24].

**Statistical analysis**

Given that the difference in neuronal injury measured by brain volumetric MRI and CCM between subjects without and with ischemic lesions in the subcortex and both subcortex and cortex have not been studied before, the results were analysed as an exploratory study and not adjusted for multiple testing or multiple comparisons [25].

Variables were summarized using means and standard deviations for numeric variables and frequency distribution for categorical variables. Variables were compared between subjects without ischemic lesions, with subcortical ischemia and both subcortical and cortical ischemia using one-way analysis of variance (ANOVA) with least significant difference (LSD) post hoc test for pairwise comparisons and categorical outcomes were compared using Chi-square test. The age-adjusted mean difference in the volume of different brain structures and corneal nerve measures between the three groups were estimated using covariance (ANCOVA) with LSD test for post hoc comparisons.

All analyses were performed using IBM-SPSS (version 26; SPSS Inc, Armonk NY). A two-tailed P value of ≤0.05 was considered significant.
Results

Demographic and clinical characteristics (Table 1)

63 subjects with MCI (n=44) and dementia (n=19) were studied. The clinical characteristics of those without ischemia (n=11), subcortical ischemia (n=32) and both cortical and subcortical ischemia (n=20) are summarized in Table 1. Gender (P=0.17), and the percentage of subjects with hypertension (P=0.51), MCI and dementia (P=0.25) were comparable between the three groups. Subjects without ischemia were significantly younger compared to those with subcortical ischemia (P<0.05) and both cortical and subcortical ischemia (P<0.01), but age was comparable between the latter two groups (P=0.30). The duration of cognitive impairment, systolic (SBP) and diastolic blood pressure (DBP), HbA1c, total cholesterol, and triglycerides were comparable between the three groups. Body weight and BMI were lower in subjects with both cortical and subcortical ischemia compared to subjects with subcortical ischemia (P=0.05) and without ischemia (P<0.05), respectively.

Cognitive function (Table 2)

Based on the MoCA, global cognitive function was significantly lower in subjects with both cortical and subcortical ischemia (P<0.05), but not those with subcortical ischemia when compared to subjects without ischemia (P=0.28). A lesser percentage of subjects with ischemia completed successfully the tests for visuospatial executive function (22.2% and 11.8% vs 63.6%, P<0.05) and orientation (44.4% and 29.4% vs 81.8%, P=0.01) were lower in subjects with ischemia compared to those without ischemia. The percentage of subjects with ischemia who successfully completed the attention test was non-significantly lower compared to those without ischemia (37.0% and 35.3% vs 72.7%, P=0.63). Performance in the other domains, including naming, sentence repetition and letter fluency, abstraction to connect related concepts and delayed recall memory test were comparable between all three groups.

Corneal nerve fiber measures (Table 2 & Figure 1)

There was no difference in corneal nerve measures between subjects with subcortical ischemia compared to those without ischemia. Corneal nerve fiber density (CNFD) (P<0.01), branch density (CNBD) (P<0.05) and fiber length (CNFL) (P<0.01) were significantly lower in subjects with both cortical and subcortical ischemia compared to those without ischemia and CNFD (P<0.05), CNBD (P<0.05) and CNFL (P<0.05) were significantly lower in subjects with both cortical and subcortical ischemia compared to those with subcortical ischemia. After adjusting for age, subjects with both cortical and subcortical ischemia had a significantly lower CNFD (-7.2 fibers/mm^2, 95% CI -14.1--0.4, P<0.05) compared to those without ischemia and a significantly lower CNFL (-4.0 mm/mm^2, 95% CI -7.5 – -0.5, P<0.05) compared to those with subcortical ischemia. There was no significant difference in the CNBD:CNFD ratio between the three groups.

Volumetric brain MRI (Table 2 & Figure 2)
Whole brain volume was significantly lower in subjects with subcortical ischemia compared to those without ischemia (P<0.05). Whole brain (P<0.01) and hippocampal volume (P<0.001) were significantly lower and ventricular volume was higher (P<0.05) in subjects with both cortical and subcortical ischemia compared to those without ischemia and hippocampal volume (P<0.01) was significantly lower and ventricular volume was higher (P<0.01) in subjects with both cortical and subcortical ischemia compared to those with subcortical ischemia. After adjusting for age, the significant difference in whole brain volume between those with and without ischemia was lost (P=0.15-0.52), whereas subjects with cortical and subcortical ischemia had a significantly lower hippocampal volume (-0.06 ICV %, 95% CI -0.10--0.02, P<0.01) and larger ventricular volume (1.27 ICV %, 95% CI 0.25-2.29, P<0.05) compared to those with subcortical ischemia but not those without ischemia (P=0.08 and 0.14, respectively). There was no significant difference in cortical gray matter, frontal, temporal, and parietal lobe volumes between the three groups.

**Peripheral neuropathy assessments (Table 2)**

Vibration perception threshold (VPT) and sudomotor function measured by electrochemical skin conductance (ESC) on the feet, were comparable between all three groups (P=0.10), even after adjusting for age (P=0.82).

**Discussion**

In this study, cortical and subcortical ischemia was associated with neurodegeneration quantified by brain volumetric MRI and corneal confocal microscopy (CCM) in patients with MCI and dementia. It was also associated with reduced global cognitive function, particularly executive function and orientation.

Unlike vascular dementia (VaD) caused by multiple or strategic infarction or hemorrhage, which develops relatively quickly in patients with stroke, mixed dementia caused by amyloid deposits and ischemic lesions develops relatively slowly [26, 27]. Ischemic lesions arise as a consequence of chronically reduced blood flow to the white matter caused by critical stenosis of the cortical medullary branches [5] and are present in approximately 50% of patients with Alzheimer's disease (AD) [28]. Indeed, ischemic lesions can be present in 11-94% of people aged ≥60 years [1] and can increase in size, shrink or in rare instances, disappear [6].

There is a need for reliable surrogate biomarkers to identify patients at a higher risk for cognitive impairment and dementia. Whilst ischemic lesions have been associated with an increase in the risk of cognitive impairment [2] and dementia [3, 4], there is scarce evidence on their association with neurodegeneration [13, 14]. Brain volumetric MRI has been suggested as a surrogate marker of neurodegeneration [13] especially as brain atrophy is associated with impairment in executive function in patients with ischemic lesions [13]. This cross-sectional study shows that ischemic lesions are associated with impaired executive function and orientation in patients with MCI and dementia. Furthermore, brain volumetric MRI showed significantly reduced hippocampal volume and increased
ventricular volume in patients with both cortical and subcortical ischemia compared to those with subcortical ischemia after adjusting for age.

This study also utilized CCM to assess if corneal nerve loss could act as a surrogate marker for the extent of cerebral ischemia. Recently, we showed that reduced corneal nerve fiber density was associated with ischemic lesions in patients with acute ischemic stroke after adjusting for age, diabetes, gender, dyslipidemia and smoking [14]. We have demonstrated significant corneal nerve loss in patients with MCI and dementia, which was associated with the severity of cognitive impairment and disability [17]. Moreover we have recently shown that the diagnostic accuracy of CCM was high and comparable with MRI based medial temporal lobe atrophy (MTA) rating for dementia but was superior in MCI [18]. This study now shows that patients with both cortical and subcortical ischemia have a significantly lower CNFD compared to those without ischemia, and significantly lower CNFL compared to those with subcortical ischemia after adjusting for. There was no significant difference in the corneal nerve measures between patients with subcortical compared to no ischemia, suggesting that more widespread ischemia is associated with corneal nerve degeneration in patients with MCI and dementia.

The prevalence of ischemic lesions increases with age [29], hypertension [7, 8] and diabetes [9, 10] and they may improve with antiplatelet therapy [11] and improved management of hypertension [7, 8] and diabetes [9, 10]. These same risk factors have been related to corneal nerve degeneration [30] and indeed improvement in blood pressure, lipids and glycemic control is associated with corneal nerve regeneration [31, 32].

A significant limitation of this study is the small sample size due to the need to exclude patients with diabetes, a confounding factor for corneal nerve loss.

**Conclusions**

This study shows that cortical and subcortical ischemia was associated with impaired global cognitive function, corneal nerve fiber loss and brain atrophy in patients with MCI and dementia. CCM and brain volumetric MRI may act as non-invasive surrogate markers of neurodegeneration associated with cortical and subcortical ischemia in patients with MCI and dementia. Further longitudinal studies are needed to evaluate the utility of CCM as a surrogate marker of neurodegeneration and progressive cognitive dysfunction.

**Abbreviations**

AD: Alzheimer’s disease

BMI: body mass index

CCM: corneal confocal microscopy
CNBD: corneal nerve branch density
CNFD: corneal nerve fiber density
CNFL: corneal nerve fiber length
ESC: electrochemical skin conductance
FT4: free thyroxine
ICV: intracranial volume
MCI: mild cognitive impairment
MoCA: Montreal Cognitive Assessment
MPRAGE: magnetization prepared rapid acquisition gradient echo sequence
MTA: medial temporal lobe atrophy
TSH: thyroid stimulating hormone
VaD: vascular dementia
VPT: Vibration perception threshold

**Declarations**

**Ethics approval and consent to participate**

Informed consent was obtained for all subjects according to the Declaration of Helsinki (1991), and protocols and procedures were approved by the Institutional Review Board of Weill Cornell Medicine in Qatar and Hamad Medical Corporation.

**Consent for publication**

All contributing authors have given their consent for the publication of this study.

**Availability of data and materials**

Data are available from the authors upon reasonable request.

**Competing interests**
The authors declare that they have no competing interests.

**Funding**

This work was funded by the Qatar National Research Fund (BMRP-5726113101 & NPRP12S-0213-190080).

**Authors’ contributions**

RAM and GP had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: AE, GP and RAM.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: GP and RAM.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: GP, ZM and RAM.

Obtained funding: RAM.

Administrative, technical, or material support: All authors.

All authors have read and approved the final manuscript.

**Acknowledgements**

We thank Dr Hanadi Al-Hamad, the Medical Director of Rumailah Hospital and Qatar Rehabilitation Institute and her staff at Rumailah Hospital for providing the facility and helping to undertake this study. We particularly thank all the participants and their relatives for their efforts, will and commitment to be involved in the study. We also thank the WCM-Q Clinical Research Core for statistical advice.

**References**

1. Debette S, Markus HS: The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. *BMJ* 2010, **341**:c3666.

2. Mungas D, Jagust WJ, Reed BR, Kramer JH, Weiner MW, Schuff N, Norman D, Mack WJ, Willis L, Chui HC: MRI predictors of cognition in subcortical ischemic vascular disease and Alzheimer's disease. *Neurology* 2001, **57**(12):2229-2235.
3. Debette S, Beiser A, DeCarli C, Au R, Himali JJ, Kelly-Hayes M, Romero JR, Kase CS, Wolf PA, Seshadri S: Association of MRI markers of vascular brain injury with incident stroke, mild cognitive impairment, dementia, and mortality: the Framingham Offspring Study. *Stroke* 2010, 41(4):600-606.

4. Prins ND, van Dijk EJ, den Heijer T, Vermeer SE, Koudstaal PJ, Oudkerk M, Hofman A, Breteler MM: Cerebral white matter lesions and the risk of dementia. *Arch Neurol* 2004, 61(10):1531-1534.

5. Roh JH, Lee JH: Recent updates on subcortical ischemic vascular dementia. *J Stroke* 2014, 16(1):18-26.

6. Wardlaw JM, Valdes Hernandez MC, Munoz-Maniega S: What are white matter hyperintensities made of? Relevance to vascular cognitive impairment. *J Am Heart Assoc* 2015, 4(6):001140.

7. de Leeuw FE, de Groot JC, Oudkerk M, Witteman JC, Hofman A, van Gijn J, Breteler MM: Hypertension and cerebral white matter lesions in a prospective cohort study. *Brain* 2002, 125(Pt 4):765-772.

8. Dufouil C, de Kersaint-Gilly A, Besancon V, Levy C, Auffray E, Brunnerau L, Alperovitch A, Tzourio C: Longitudinal study of blood pressure and white matter hyperintensities: the EVA MRI Cohort. *Neurology* 2001, 56(7):921-926.

9. McNay EC: The impact of recurrent hypoglycemia on cognitive function in aging. *Neurobiol Aging* 2005, 26 Suppl 1:76-79.

10. Geijseraers SLC, Sep SJS, Claessens D, Schram MT, van Boxtel MPJ, Henry RMA, Verhey FRJ, Kroon AA, Dagnelie PC, Schalkwijk CG et al: The Role of Hyperglycemia, Insulin Resistance, and Blood Pressure in Diabetes-Associated Differences in Cognitive Performance-The Maastricht Study. *Diabetes Care* 2017, 40(11):1537-1547.

11. Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM, Iadecola C, Launer LJ, Laurent S, Lopez OL, Nyenhuis D et al: Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association. *Stroke* 2011, 42(9):2672-2713.

12. Pantoni L, Bianchi C, Beneke M, Inzitari D, Wallin A, Erkinjuntti T: The Scandinavian Multi-Infarct Dementia Trial: a double-blind, placebo-controlled trial on nimodipine in multi-infarct dementia. *J Neurol Sci* 2000, 175(2):116-123.

13. Nitkunan A, Lanfranconi S, Charlton RA, Barrick TR, Markus HS: Brain atrophy and cerebral small vessel disease: a prospective follow-up study. *Stroke* 2011, 42(1):133-138.

14. Kamran S, Khan A, Salam A, Akhtar N, Petropoulos I, Ponirakis G, Babu B, George P, Shuaib A, Malik RA: Cornea: A Window to White Matter Changes in Stroke; Corneal Confocal Microscopy a Surrogate Marker for the Presence and Severity of White Matter Hyperintensities in Ischemic Stroke. *J Stroke Cerebrovasc Dis* 2020:104543.

15. Gad H, Khan A, Akhtar N, Kamran S, El-Sotouhy A, Dargham SR, Petropoulos IN, Ponirakis G, Shuaib A, Streletz LJ et al: Correction: Corneal nerve and endothelial cell damage in patients with transient ischemic attack and minor ischemic stroke. *PLoS One* 2019, 14(5):e0217672.

16. Khan A, Kamran S, Akhtar N, Ponirakis G, Al-Muhannadi H, Petropoulos IN, Al-Fahdawi S, Qahwaji R, Sartaj F, Babu B et al: Corneal Confocal Microscopy detects a Reduction in Corneal Endothelial Cells
and Nerve Fibres in Patients with Acute Ischemic Stroke. *Sci Rep* 2018, 8(1):17333.

17. Ponirakis G, Al Hamad H, Sankaranarayanan A, Khan A, Chandran M, Ramadan M, Tosino R, Gawhale PV, Alobaidi M, AlSulaiti E et al. **Association of corneal nerve fiber measures with cognitive function in dementia.** *Ann Clin Transl Neurol* 2019, 6(4):689-697.

18. Al-Janahi E, Ponirakis G, Al Hamad H, Vattoth S, Elsotouhy A, Petropoulos IN, Khan A, Gad H, Chandran M, Sankaranarayanan A et al. **Corneal Nerve and Brain Imaging in Mild Cognitive Impairment and Dementia.** *J Alzheimers Dis* 2020.

19. Tavakoli M, Quattrini C, Abbott C, Kallinikos P, Marshall A, Finnigan J, Morgan P, Efron N, Boulton AJ, Malik RA: **Corneal confocal microscopy: a novel noninvasive test to diagnose and stratify the severity of human diabetic neuropathy.** *Diabetes Care* 2010, 33(8):1792-1797.

20. Organization WH: **The ICD-10 classification of mental and behavioural disorders : clinical descriptions and diagnostic guidelines.** Geneva: World Health Organization 1992.

21. Brewer JB, Magda S, Airriess C, Smith ME: **Fully-automated quantification of regional brain volumes for improved detection of focal atrophy in Alzheimer disease.** *AJNR Am J Neuroradiol* 2009, 30(3):578-580.

22. Stelmokas J, Yassay L, Giordani B, Dodge HH, Dinov ID, Bhaumik A, Sathian K, Hampstead BM: **Translational MRI Volumetry with NeuroQuant: Effects of Version and Normative Data on Relationships with Memory Performance in Healthy Older Adults and Patients with Mild Cognitive Impairment.** *J Alzheimers Dis* 2017, 60(4):1499-1510.

23. Kalteniece A, Ferdousi M, Adam S, Schofield J, Azmi S, Petropoulos I, Soran H, Malik RA: **Corneal confocal microscopy is a rapid reproducible ophthalmic technique for quantifying corneal nerve abnormalities.** *PLoS One* 2017, 12(8):e0183040.

24. Dabbah MA, Graham J, Petropoulos IN, Tavakoli M, Malik RA: **Automatic analysis of diabetic peripheral neuropathy using multi-scale quantitative morphology of nerve fibres in corneal confocal microscopy imaging.** *Medical image analysis* 2011, 15(5):738-747.

25. Rothman KJ: **No adjustments are needed for multiple comparisons.** *Epidemiology* 1990, 1(1):43-46.

26. Pendlebury ST, Rothwell PM: **Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis.** *Lancet Neurol* 2009, 8(11):1006-1018.

27. Pendlebury ST: **Stroke-related dementia: rates, risk factors and implications for future research.** *Maturitas* 2009, 64(3):165-171.

28. Wang BW, Lu E, Mackenzie IR, Assaly M, Jacova C, Lee PE, Beattie BL, Hsiung GY: **Multiple pathologies are common in Alzheimer patients in clinical trials.** *Can J Neurol Sci* 2012, 39(5):592-599.

29. Smith EE, Saposnik G, Biessels GJ, Doubal FN, Fornage M, Gorelick PB, Greenberg SM, Higashida RT, Kasner SE, Seshadri S et al: **Prevention of Stroke in Patients With Silent Cerebrovascular Disease: A Scientific Statement for Healthcare Professionals From the American Heart Association/American Stroke Association.** *Stroke* 2017, 48(2):e44-e71.
30. Ponirakis G, Petropoulos IN, Alam U, Ferdousi M, Asghar O, Marshall A, Azmi S, Jeziorska M, Mahfoud ZR, Boulton AJM et al: Hypertension Contributes to Neuropathy in Patients With Type 1 Diabetes. *Am J Hypertens* 2019, 32(8):796-803.

31. Tavakoli M, Kallinikos P, Iqbal A, Herbert A, Fadavi H, Efron N, Boulton AJ, R AM: Corneal confocal microscopy detects improvement in corneal nerve morphology with an improvement in risk factors for diabetic neuropathy. *Diabet Med* 2011, 28(10):1261-1267.

32. Azmi S, Jeziorska M, Ferdousi M, Petropoulos IN, Ponirakis G, Marshall A, Alam U, Asghar O, Atkinson A, Jones W et al: Early nerve fibre regeneration in individuals with type 1 diabetes after simultaneous pancreas and kidney transplantation. *Diabetologia* 2019, 62(8):1478-1487.

### Tables

**Table 1.** Demographic and clinical characteristics in subjects with mild cognitive impairment or dementia and no ischemia, subcortical ischemia and both cortical and subcortical ischemia.
|                              | No ischemia (n = 11) | Subcortical ischemia (n = 32) | Cortical & subcortical ischemia (n = 20) | P value¹ | P value² | P value³ |
|------------------------------|----------------------|-------------------------------|-----------------------------------------|----------|----------|----------|
| Mild cognitive impairment, n (%) | 10 (22.7)            | 21 (47.7)                     | 13 (29.5)                               | P value = 0.25 |
| Dementia                     | 1 (5.3)              | 11 (57.9)                     | 7 (36.8)                                |           |          |          |
| Age, years                   | 63.0 ± 7.3           | 70.0 ± 8.8                    | 72.5 ± 7.5                              | <0.05    | <0.01    | 0.30     |
| Duration of cognitive impairment | 3.9 ± 5.9            | 2.0 ± 1.9                     | 2.6 ± 2.3                               | 0.11     | 0.27     | 0.57     |
| Female, n (%)                | 7 (28.0)             | 12 (48.0)                     | 6 (24.0)                                | P value = 0.17 |
| Hypertension, n (%)          | 7 (63.6)             | 16 (50.0)                     | 13 (65.0)                               | P value = 0.51 |
| Systolic BP, mmHg            | 137.9 ± 18           | 135.8 ± 13.3                  | 141.1 ± 24.8                            | 0.69     | 0.66     | 0.28     |
| Diastolic BP, mmHg           | 76.7 ± 8.6           | 73.3 ± 7.1                    | 73.9 ± 8.4                              | 0.24     | 0.28     | 0.99     |
| Weight, kg                   | 74.1 ± 19.3          | 82.4 ± 16.1                   | 72.6 ± 12.3                             | 0.17     | 0.79     | 0.05     |
| BMI, kg/m²                   | 28.7 ± 7.4           | 31.8 ± 6.7                    | 27.3 ± 4.9                              | 0.17     | 0.56     | <0.05    |
| HbA1c, %                     | 5.7 ± 0.5            | 5.6 ± 0.6                     | 5.6 ± 0.3                               | 0.83     | 0.84     | 0.99     |
| Total cholesterol, mmol/L    | 4.8 ± 0.6            | 4.9 ± 1.2                     | 5.2 ± 0.7                               | 0.89     | 0.38     | 0.34     |
| Triglycerides, mmol/L        | 1.1 ± 0.6            | 1.4 ± 0.7                     | 1.5 ± 0.9                               | 0.34     | 0.20     | 0.60     |

¹No ischemia versus subcortical ischemia

²No ischemia versus cortical & subcortical ischemia

³Subcortical ischemia versus cortical & subcortical ischemia

Data from 63 subjects presented as mean ± standard deviation for numeric variables and frequency distribution for categorical variables. Continuous and categorical variables were compared using one-way ANOVA with LSD test for post hoc comparisons and Chi-square test, respectively.
Table 2. Comparison of cognitive function, corneal nerve fiber morphology and volumetric brain MRI in subjects with mild cognitive impairment and dementia between no ischemia, subcortical ischemia and both cortical and subcortical ischemia.

|                               | No ischemia (n = 11) | Subcortical ischemia (n = 32) | Cortical & subcortical ischemia (n = 20) | P value<sup>1</sup> | P value<sup>2</sup> | P value<sup>3</sup> |
|-------------------------------|----------------------|--------------------------------|----------------------------------------|---------------------|---------------------|---------------------|
| MoCA                         | 24.3 ± 5.7           | 20.8 ± 6.0                     | 18.8 ± 6.1                             | 0.10                | <0.05               | 0.28                |
| CNFD, fibers/mm<sup>2</sup>   | 31.2 ± 6.7           | 27.0 ± 9.0                     | 21.7 ± 9.1                             | 0.18                | <0.01               | <0.05               |
| CNBD, branches/mm<sup>2</sup> | 78.3 ± 33.5          | 69.6 ± 45.4                    | 46.4 ± 28.5                            | 0.53                | <0.05               | <0.05               |
| CNFL, mm/mm<sup>2</sup>       | 21.2 ± 5.1           | 19.3 ± 6.9                     | 14.9 ± 5.8                             | 0.39                | <0.01               | <0.05               |
| CNBD:CNFD ratio               | 2.5 ± 0.9            | 2.5 ± 1.2                      | 2.2 ± 1.4                              | 1.00                | 0.51                | 0.39                |
| VPT, Volts                    | 16.5 ± 13.4          | 18.3 ± 8.7                     | 18.6 ± 10.4                            | 0.65                | 0.61                | 0.93                |
| ESC feet, µS                  | 62.4 ± 18.9          | 58.7 ± 18.5                    | 54.6 ± 20.4                            | 0.65                | 0.36                | 0.48                |
| Cortical gray matter, ICV %   | 28.9 ± 3.5           | 28.2 ± 3.8                     | 27.3 ± 4.1                             | 0.63                | 0.29                | 0.42                |
| Hippocampus, ICV %            | 0.47 ± 0.08          | 0.43 ± 0.08                    | 0.35 ± 0.07                            | 0.24                | 0.001               | <0.01               |
| Ventricle, ICV %              | 2.6 ± 2.0            | 3.0 ± 1.9                      | 4.4 ± 1.3                              | 0.58                | <0.05               | 0.01                |
| Frontal lobe, ICV %           | 10.6 ± 1.1           | 10.2 ± 1.6                     | 9.6 ± 1.5                              | 0.50                | 0.11                | 0.20                |
| Temporal lobe, ICV %          | 7.4 ± 1.1            | 7.4 ± 1.1                      | 7.0 ± 1.2                              | 1.00                | 0.34                | 0.20                |
| Parietal lobe, ICV %          | 6.8 ± 1.1            | 6.2 ± 0.9                      | 6.1 ± 0.8                              | 0.10                | 0.07                | 0.76                |
| Whole brain, ICV %            | 74.1 ± 3.1           | 71.0 ± 4.6                     | 69.2 ± 3.2                             | 0.05                | <0.01               | 0.14                |

<sup>1</sup>No ischemia versus subcortical ischemia

<sup>2</sup>No ischemia versus cortical & subcortical ischemia

<sup>3</sup>Subcortical ischemia versus cortical & subcortical ischemia
Data from 63 subjects presented as mean ± standard deviation for numeric variables and frequency distribution for categorical variables. Continuous and categorical variables were compared using one-way ANOVA with LSD test for post hoc comparisons and Chi-square test, respectively. Abbreviations: Montreal cognitive assessment (MoCA); Corneal nerve fiber density (CNFD); length (CNFL), branch density (CNBD), vibration perception threshold (VPT), electrochemical skin conductance (ESC) and intra cranial volume (ICV).